Zachary Klaassen speaks with Jie Luo about his Prostate Cancer Foundation Young Investigator Award work on androgen receptor enhanceosomes in prostate cancer. Dr. Luo explains that enhanceosomes are ...
Pedro Barata is joined by Brian Shuch to discuss his investigator-initiated phase 2 trial evaluating girentuximab PET-CT imaging for detecting residual disease after nephrectomy in clear cell renal ...
Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Artificial intelligence (AI) is reshaping the landscape of men's health by enhancing diagnostic accuracy, personalizing treatment strategies, and improving clinical efficiency. This narrative review ...
Read the Full Video Transcript Andrea Miyahira: Hi, everyone. I'm Andrea Miyahira with the Prostate Cancer Foundation. Thank you for joining me for a special Women in Science episode. And joining me ...
Eric Kim interviews Aaron Berger about treatment approaches for high-risk prostate cancer and biochemical recurrence. Dr. Berger explains his balanced approach to treatment selection between surgery ...
At the 2025 UCSF-UCLA PSMA Conference, Thomas Hope challenges using PSMA PET/CT for restaging during radioligand therapy, advocating instead for post-treatment SPECT/CT imaging. While both modalities ...
At the 2025 UCSF-UCLA PSMA Conference, Tanya Stoyanova discusses TROP2 as a promising alternative target for prostate cancer imaging and radiotherapy. She highlights that 25% of metastatic ...
Read the Full Video Transcript Ashish Kamat: Hello everybody, and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, professor of urologic oncology at M.D. Anderson Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results